Serum levels of TIMP-1 and TIMP-2 are elevated in patients with pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003
Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension Source: Eur Respir J 2001; 18: 838-845 Year: 2001
Decrease in circulating monocyte metalloproteinase-9 content with increasing severity of pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 5s Year: 2002
Increased concentration of matrix metalloproteinase-9 in serum of COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 54s Year: 2005
Relationship between circulating serpina 3g, activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, 2 with chronic obstructive pulmonary disease severity Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018
Increased EMMPRIN and MT1-MMP levels in the plasma of the stable adult patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 404s Year: 2005
MMP-9 and TIMP-1 expression in acute lung injury rats with diabetes Source: Eur Respir J 2004; 24: Suppl. 48, 557s Year: 2004
Expression of elastolytic matrix metalloproteinases in bleomycin-induced pulmonary fibrosis Source: Eur Respir J 2002; 20: Suppl. 38, 228s Year: 2002
Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2005; 25: 834-842 Year: 2005
The role of matrix metalloproteinase- 9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMMP-1) in sarcoidosis and idiopathic pulmonary fibrosis. Correlation with echocardiography Source: Eur Respir J 2006; 28: Suppl. 50, 745s Year: 2006
Matrix metalloproteinases and their inhibitors in pulmonary hypertension}, Source: Eur Respir J 2012; 40: 766-782 Year: 2012
Circulating matrix metalloproteinase-9 (MMP-9) is associated with the extension of lung disease in patients with active tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 35s Year: 2004
Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients Source: Eur Respir J 2005; 25: 885-890 Year: 2005
BIBF1120 inhibits fibroblasts proliferation and production of the extracellular matrix protein fibulin-1 Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015
MMP expression and abnormal lung permeability are important determinants of outcome in IPF Source: Eur Respir J 2009; 33: 77-84 Year: 2009
Role of matrix metalloproteinases in progression of idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010
Expression of matrix metalloproteinases and TIMP inhibitors in circulation/lung in patients with chronic obstructive pulmonary disease Source: Annual Congress 2012 - Asthma and COPD: understanding through mechanisms Year: 2012
Increased expression of MMP-2 in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 361s Year: 2005
Serum levels of microRNA-125a are decreased in patients with precapillary pulmonary hypertension and correlate inversely with hemodynamics Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013
Are there serum levels of MMP-2 and MMP-9 may be markers of COPD phenotypes? Source: Annual Congress 2012 - COPD treatment and varia Year: 2012